bluebird bio (BLUE) to Release Quarterly Earnings on Monday

bluebird bio (NASDAQ:BLUE) is anticipated to announce its earnings results on Monday, March 24th. Analysts expect the company to announce earnings of ($6.30) per share and revenue of $27.07 million for the quarter.

bluebird bio Price Performance

bluebird bio stock opened at $3.75 on Monday. The stock’s fifty day moving average price is $6.46 and its two-hundred day moving average price is $8.24. bluebird bio has a one year low of $3.56 and a one year high of $30.90. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The firm has a market cap of $36.46 million, a PE ratio of -0.10 and a beta of 0.76.

Analysts Set New Price Targets

A number of research firms have commented on BLUE. Wells Fargo & Company lowered their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th. StockNews.com began coverage on bluebird bio in a research note on Wednesday, March 12th. They set a “sell” rating on the stock. Barclays raised their price objective on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 31st. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Finally, Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, bluebird bio has an average rating of “Hold” and an average target price of $48.10.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.